Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 17/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18198056 | 0.93 | NR1H4 (0.69) | NR1H4MAPTPOLB | |
| SCHEMBL18198057 | 0.90 | NR1H4 (0.66) | NR1H4MAPTPOLB | |
| SCHEMBL16702461 | 0.89 | NR1H4 (0.85) | NR1H4MAPTPOLB | |
| SCHEMBL18198085 | 0.89 | NR1H4 (0.62) | NR1H4MAPTPOLB | |
| SCHEMBL18191644 | 0.89 | NR1H4 (0.60) | NR1H4MAPTPOLB | |
| SCHEMBL18198058 | 0.87 | NR1H4 (0.64) | NR1H4MAPTPOLB | |
| SCHEMBL16702933 | 0.87 | NR1H4 (0.65) | NR1H4MAPTPOLB | |
| SCHEMBL18191592 | 0.86 | NR1H4 (0.79) | NR1H4MAPTPOLB | |
| SCHEMBL18198054 | 0.85 | NR1H4 (0.61) | NR1H4MAPTPOLB | |
| SCHEMBL16702534 | 0.85 | NR1H4 (0.80) | NR1H4MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3288948-B1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-10351576-B2 | Fused tricyclic pyrazole derivatives useful for farnesoid X receptors | NOVARTIS AG (CH) | 2019-07-16 | — | — | US | disclosed |
| WO-2016174616-A1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351576-B2 | Fused tricyclic pyrazole derivatives useful for farnesoid X receptors | NR1H4, FXR1, GPBAR1 | NR1H4 1/4885MAPT 3926/4885POLB 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.